Covid 19 Research using Clinical Trials (Home Page)
HP:0012288: Neoplasm of head and neckHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2207 | Screening test for covid ( RT PCR and CT Chest) Wiki | 0.71 |
| drug1808 | Photobiomodulation Wiki | 0.71 |
| drug2113 | Routine Oral Care and Analgesia Wiki | 0.71 |
There are 2 clinical trials
Clinical Trials
1 Photobiomodulation Therapy Using the MuReva Phototherapy System to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Patients With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy
The overall purpose of this clinical study is to evaluate safety and efficacy of the MuReva Phototherapy System with a light delivery mouthpiece to reduce the incidence of severe oral mucositis (OM) in adult patients with squamous cell carcinoma of the oral cavity, oropharynx, tonsils and base of tongue receiving concurrent radiation and chemotherapy.
NCT03972527 Oral Mucositis (Ulcerative) Oral Mucositis (Ulcerative) Due to Radiation Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy Head and Neck Cancer Device: Photobiomodulation Other: Routine Oral Care and Analgesia MeSH:Gingivitis, Necrotizing Ulcerative Head and Neck Neoplasms Mucositis Stomatitis Ulcer
HPO:Neoplasm of head and neck Stomatitis
Primary Outcomes
Description: The primary effectiveness endpoint of the study is the proportion of patients who have severe oral mucositis (Grade 3 or 4) at week 6 of treatment according to the World Health Organization (WHO) Oral Toxicity Scale.
Measure: Incidence of severe oral mucositis (WHO grade 3 and 4) at week 6 of chemoradiation therapy. Time: 6-8 weeks of photobiomodulation and chemoradiation therapy
Secondary Outcomes
Description: Radiation therapy oncology group scale (RTOG) 0 (Normal)- 4 (necrosis/hemorrhage), 5= death
Measure: Oral Mucositis (OM) Grade and Incidence, Time: 6-8 weeks, evaluated once per week
Description: World Health Organization scale (WHO) 0 (Normal)- 4 (oral alimentation not possible), 5= death
Measure: Oral Mucositis (OM) Grade and Incidence, Time: 6-8 weeks, evaluated once per week
Description: World Health Organization (WHO) analgesic ladder Steps 1-3: 1= non opioid, 2= weak opioid, 3= strong opioid
Measure: Analgesic Usage Time: 6-8 weeks, evaluated daily
2 Surgical Activity During the Covid-19 Pandemic: Results for 112 Patients in a French Tertiary Care Center: A Retrospective Observational Cohort Study
Primary Outcomes
Description: The primary effectiveness endpoint of the study is the proportion of patients who have severe oral mucositis (Grade 3 or 4) at week 6 of treatment according to the World Health Organization (WHO) Oral Toxicity Scale.
Measure: Incidence of severe oral mucositis (WHO grade 3 and 4) at week 6 of chemoradiation therapy. Time: 6-8 weeks of photobiomodulation and chemoradiation therapySecondary Outcomes
Description: Radiation therapy oncology group scale (RTOG) 0 (Normal)- 4 (necrosis/hemorrhage), 5= death
Measure: Oral Mucositis (OM) Grade and Incidence, Time: 6-8 weeks, evaluated once per weekDescription: World Health Organization scale (WHO) 0 (Normal)- 4 (oral alimentation not possible), 5= death
Measure: Oral Mucositis (OM) Grade and Incidence, Time: 6-8 weeks, evaluated once per weekDescription: World Health Organization (WHO) analgesic ladder Steps 1-3: 1= non opioid, 2= weak opioid, 3= strong opioid
Measure: Analgesic Usage Time: 6-8 weeks, evaluated dailyBackground After the emergence of Covid-19 in China, Hubei Province, the epidemic quickly spread to Europe. France was quickly hit and the Croix-Rousse hospital at the Hospices Civils de Lyon was one of the first French university hospital to receive patients infected with Sars-COV2. The predicted massive influx of patients motivated the cancellation of all elective surgical procedures planned to free hospitalization beds and to free intensive care beds. Nevertheless, patients who had to be canceled had to be properly selected to avoid a life threatening. The retained surgical indications were surgical emergencies, oncologic surgery and organ transplantation. The objective was to describe the organization of the Croix-Rousse hospital to allow the continuation of these surgical activities while limiting the exposure of patients to the Sars Cov2.
NCT04379232 Digestive Cancer Gynaecological Cancer Head and Neck Cancer Biological: Screening test for covid ( RT PCR and CT Chest) MeSH:Head and Neck Neoplasms
HPO:Neoplasm of head and neck
Primary Outcomes
Description: Patients are tested with RT PCR and CT Chest if they declare symptoms after surgery
Measure: Symptoms of Covid after surgery Time: Screening test are performed if the patient becomes symptomatic up to 14 days after surgery. In case of symptoms patients are tested within 24 hours.
HPO Nodes
Primary Outcomes
Description: Patients are tested with RT PCR and CT Chest if they declare symptoms after surgery
Measure: Symptoms of Covid after surgery Time: Screening test are performed if the patient becomes symptomatic up to 14 days after surgery. In case of symptoms patients are tested within 24 hours.